NCT06948981View on ClinicalTrials.gov

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

April 17, 2028

Study Completion Date

April 17, 2028

Conditions

Hematological Malignancy (Leukemia- Lymphoma)

Interventions

BIOLOGICAL

GT719 Injection

GT719 Injection

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

lead

Grit Biotechnology

INDUSTRY